Skip to main content Skip to footer
HomeHome
 
  • Startseite
  • Patentrecherche

    Patentwissen

    Unsere Patentdatenbanken und Recherchetools

    Zur Übersicht 

    • Übersicht
    • Technische Information
      • Übersicht
      • Espacenet - Patentsuche
      • Europäischer Publikationsserver
      • EP-Volltextrecherche
    • Rechtliche Information
      • Übersicht
      • Europäisches Patentregister
      • Europäisches Patentblatt
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Übersicht
      • PATSTAT
      • IPscore
      • Technologieanalyseberichte
    • Daten
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
      • Web-Dienste
      • Datenbestände, Codes und Statistiken
    • Technologieplattformen
      • Übersicht
      • Kunststoffe im Wandel
      • Innovationen im Wassersektor
      • Innovationen im Weltraumsektor
      • Technologien zur Bekämpfung von Krebs
      • Technologien zur Brandbekämpfung
      • Saubere Energietechnologien
      • Kampf gegen Corona
    • Nützliche Informationsquellen
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
      • Patentinformation aus Asien
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
    Bild
    Plastics in Transition

    Technologieanalysebericht zur Plastikabfallwirtschaft

  • Anmelden eines Patents

    Anmelden eines Patents

    Praktische Informationen über Anmelde- und Erteilungsverfahren.

    Zur Übersicht 

    • Übersicht
    • Europäischer Weg
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
      • Nationale Validierung
      • Antrag auf Erstreckung/Validierung
    • Internationaler Weg (PCT)
      • Übersicht
      • Euro-PCT-Leitfaden: PCT-Verfahren im EPA
      • Beschlüsse und Mitteilungen des EPA
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
      • Schulungen und Veranstaltungen
    • Nationale Anmeldungen
    • Zugelassenen Vertreter suchen
    • MyEPO Services
      • Übersicht
      • Unsere Dienste verstehen
      • Zugriff erhalten
      • Bei uns einreichen
      • Akten interaktiv bearbeiten
      • Verfügbarkeit der Online-Dienste
    • Formblätter
      • Übersicht
      • Prüfungsantrag
    • Gebühren
      • Übersicht
      • Europäische Gebühren (EPÜ)
      • Internationale Gebühren (PCT)
      • Einheitspatentgebühren (UP)
      • Gebührenzahlung und Rückerstattung
      • Warnung

    UP

    Erfahren Sie, wie das Einheitspatent Ihre IP-Strategie verbessern kann

  • Recht & Praxis

    Recht & Praxis

    Europäisches Patentrecht, Amtsblatt und andere Rechtstexte

    Zur Übersicht 

    • Übersicht
    • Rechtstexte
      • Übersicht
      • Europäisches Patentübereinkommen
      • Amtsblatt
      • Richtlinien
      • Erstreckungs-/ Validierungssyste
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
      • Système du brevet unitaire
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
    Bild
    Law and practice scales 720x237

    Informieren Sie sich über die wichtigsten Aspekte ausgewählter BK-Entscheidungen in unseren monatlichen „Abstracts of decisions“

  • Neues & Veranstaltungen

    Neues & Veranstaltungen

    Aktuelle Neuigkeiten, Podcasts und Veranstaltungen.

    Zur Übersicht 

     

    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Übersicht
      • Die bedeutung von morgen
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Finalisten kennen
      • Nominierungen
      • European Inventor Network
      • Preisverleihung 2024
    • Young Inventor Prize
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die jury
      • Die Welt, neu gedacht
    • Pressezentrum
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Innovation und Patente im Blickpunkt
      • Übersicht
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
      • Zukunft der Medizin
      • Werkstoffkunde
      • Mobile Kommunikation: Das große Geschäft mit kleinen Geräten
      • Biotechnologiepatente
      • Patentklassifikation
      • Digitale Technologien
      • Die Zukunft der Fertigung
      • Books by EPO experts
    • Podcast "Talk innovation"

    Podcast

    Von der Idee zur Erfindung: unser Podcast informiert Sie topaktuell in Sachen Technik und IP

  • Lernen

    Lernen

    Europäische Patentakademie – unser Kursportal für Ihre Fortbildung

    Zur Übersicht 

    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Übersicht
      • Schulungsaktivitäten
      • Lernpfade
    • EEP und EPVZ
      • Übersicht
      • EEP – Europäische Eignungsprüfung
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Lernmaterial nach Interesse
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Durchsetzung
    • Lernmaterial nach Profil
      • Übersicht
      • Geschäftswelt und IP
      • EEP und EPVZ Bewerber
      • Justiz
      • Nationale Ämter und IP-Behörden
      • Patentanwaltskanzleien
      • Lehre und Forschung
    Bild
    Patent Academy catalogue

    Werfen Sie einen Blick auf das umfangreiche Lernangebot im Schulungskatalog der Europäischen Patentakademie

  • Über uns

    Über uns

    Erfahren Sie mehr über Tätigkeit, Werte, Geschichte und Vision des EPA

    Zur Übersicht 

    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre Europäisches Patentübereinkommen
      • Übersicht
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten der Europäischen Patentorganisation
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Übersicht
      • Kommuniqués
      • Kalender
      • Dokumente und Veröffentlichungen
      • Der Verwaltungsrat der Europäischen Patentorganisation
    • Unsere Grundsätze und Strategie
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategischer Plan 2028
      • Auf dem Weg zu einer neuen Normalität
    • Führung und Management
      • Übersicht
      • Präsident António Campinos
      • Managementberatungsausschuss
    • Sustainability at the EPO
      • Übersicht
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Dienste & Aktivitäten
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
      • Nutzerkonsultation
      • Europäische und internationale Zusammenarbeit
      • Europäische Patentakademie
      • Chefökonom
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Übersicht
      • Akteure im Innovationsbereich
      • Politisches Umfeld und Finanzierung
      • Tools
      • Über die Beobachtungsstelle
    • Beschaffung
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Nachhaltiger Beschaffungsstandard
      • Registrierung zum eTendering und elektronische Signaturen
      • Beschaffungsportal
      • Rechnungsstellung
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Transparenzportal
      • Übersicht
      • Allgemein
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Die Geschichte des EPA
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Die EPA Kunstsammlung
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
      • "Lange Nacht"
    Bild
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Verfolgen Sie die neuesten Technologietrends mit unserem Patentindex

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • Sind Patente Neuland für Sie?
  • Sind Patente Neuland für Sie?
    • Go back
    • Patente für Ihr Unternehmen?
    • Warum ein Patent?
    • Was ist Ihre zündende Idee?
    • Sind Sie bereit?
    • Darum geht es
    • Der Weg zum Patent
    • Ist es patentierbar?
    • Ist Ihnen jemand zuvorgekommen?
    • Patentquiz
    • Video zum Einheitspatent
  • Patentrecherche
    • Go back
    • Übersicht
    • Technische Information
      • Go back
      • Übersicht
      • Espacenet - Patentsuche
        • Go back
        • Übersicht
        • Datenbanken der nationalen Ämter
        • Global Patent Index (GPI)
        • Versionshinweise
      • Europäischer Publikationsserver
        • Go back
        • Übersicht
        • Versionshinweise
        • Konkordanzliste für Euro-PCT-Anmeldungen
        • EP-Normdatei
        • Hilfe
      • EP-Volltextrecherche
    • Rechtliche Information
      • Go back
      • Übersicht
      • Europäisches Patentregister
        • Go back
        • Übersicht
        • Versionshinweise: Archiv
        • Dokumentation zu Register
          • Go back
          • Übersicht
          • Datenverfügbarkeit für Deep Links
          • Vereinigtes Register
          • Ereignisse im Register
      • Europäisches Patentblatt
        • Go back
        • Übersicht
        • Patentblatt herunterladen
        • Recherche im Europäischen Patentblatt
        • Hilfe
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Go back
      • Übersicht
      • PATSTAT
      • IPscore
        • Go back
        • Versionshinweise
      • Technologieanalyseberichte
    • Daten
      • Go back
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
        • Go back
        • Übersicht
        • Manuals
        • Sequenzprotokolle
        • Nationale Volltextdaten
        • Daten des Europäischen Patentregisters
        • Weltweite bibliografische Daten des EPA (DOCDB)
        • EP-Volltextdaten
        • Weltweite Rechtsereignisdaten des EPA (INPADOC)
        • Bibliografische Daten von EP-Dokumenten (EBD)
        • Entscheidungen der Beschwerdekammern des EPA
      • Web-Dienste
        • Go back
        • Übersicht
        • Open Patent Services (OPS)
        • Europäischer Publikationsserver (Web-Dienst)
      • Datenbestände, Codes und Statistiken
        • Go back
        • Wöchentliche Aktualisierungen
        • Regelmäßige Aktualisierungen
    • Technologieplattformen
      • Go back
      • Kunststoffe im Wandel
        • Go back
        • Overview
        • Verwertung von Plastikabfällen
        • Recycling von Plastikabfällen
        • Alternative Kunststoffe
      • Übersicht
      • Innovative Wassertechnologien
        • Go back
        • Overview
        • Sauberes Wasser
        • Schutz vor Wasser
      • Innovationen im Weltraumsektor
        • Go back
        • Übersicht
        • Kosmonautik
        • Weltraumbeobachtung
      • Technologien zur Bekämpfung von Krebs
        • Go back
        • Übersicht
        • Prävention und Früherkennung
        • Diagnostik
        • Therapien
        • Wohlergehen und Nachsorge
      • Technologien zur Brandbekämpfung
        • Go back
        • Übersicht
        • Branderkennung und -verhütung
        • Feuerlöschen
        • Schutzausrüstung
        • Technologien für die Sanierung nach Bränden
      • Saubere Energietechnologien
        • Go back
        • Übersicht
        • Erneuerbare Energien
        • CO2-intensive Industrien
        • Energiespeicherung und andere Enabling-Technologien
      • Kampf gegen Corona
        • Go back
        • Übersicht
        • Impfstoffe und Therapeutika
          • Go back
          • Übersicht
          • Impfstoffe
          • Übersicht über Therapieansätze für COVID-19
          • Kandidaten für antivirale Therapeutika
          • Nukleinsäuren zur Behandlung von Coronavirus-Infektionen
        • Diagnose und Analyse
          • Go back
          • Übersicht
          • Protein-und Nukleinsäure-Nachweis
          • Analyseprotokolle
        • Informatik
          • Go back
          • Übersicht
          • Bioinformatik
          • Medizinische Informatik
        • Technologien für die neue Normalität
          • Go back
          • Übersicht
          • Geräte, Materialien und Ausrüstung
          • Verfahren, Maßnahmen und Aktivitäten
          • Digitale Technologien
        • Erfinderinnen und Erfinder gegen das Coronavirus
    • Nützliche Informationsquellen
      • Go back
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
        • Go back
        • Übersicht
        • Grundlegende Definitionen
        • Patentklassifikation
          • Go back
          • Übersicht
          • Gemeinsame Patentklassifikation
        • Patentfamilien
          • Go back
          • Übersicht
          • Einfache DOCDB Patentfamilie
          • Erweiterte INPADOC Patentfamilie
        • Daten zu Rechtsstandsereignissen
          • Go back
          • Übersicht
          • INPADOC-Klassifikationssystem
      • Patentinformation aus Asien
        • Go back
        • Übersicht
        • China (CN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinesisch-Taipei (TW)
          • Go back
          • Übersicht
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Indien (IN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russische Föderation (RU)
          • Go back
          • Übersicht
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
  • Anmelden eines Patents
    • Go back
    • Übersicht
    • Europäischer Weg
      • Go back
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
        • Go back
        • Kalender der mündlichen Verhandlungen
          • Go back
          • Kalender der mündlichen Verhandlungen
          • Technische Richtlinien
          • Zugang für die Öffentlichkeit zum Beschwerdeverfahren
          • Zugang für die Öffentlichkeit zum Einspruchsverfahren
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
        • Go back
        • Einheitspatent
          • Go back
          • Übersicht
          • Rechtlicher Rahmen
          • Wesentliche Merkmale
          • Beantragung eines Einheitspatents
          • Kosten eines Einheitspatents
          • Übersetzungsregelungen und Kompensationssystem
          • Starttermin
          • Introductory brochures
        • Übersicht
        • Einheitliches Patentgericht
      • Nationale Validierung
      • Erstreckungs- /Validierungsantrag
    • Internationaler Weg
      • Go back
      • Übersicht
      • Euro-PCT-Leitfaden
      • Eintritt in die europäische Phase
      • Beschlüsse und Mitteilungen
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programm "Patent Prosecution Highway" (PPH) - Übersicht
      • PCT: Schulungen und Veranstaltungen
    • Nationaler Weg
    • MyEPO Services
      • Go back
      • Übersicht
      • Unsere Dienste verstehen
        • Go back
        • Übersicht
        • Exchange data with us using an API
          • Go back
          • Versionshinweise
      • Zugriff erhalten
        • Go back
        • Übersicht
        • Versionshinweise
      • Bei uns einreichen
        • Go back
        • Bei uns einreichen
        • Wenn unsere Dienste für die Online-Einreichung ausfallen
        • Versionshinweise
      • Akten interaktiv bearbeiten
        • Go back
        • Versionshinweise
      • Verfügbarkeit der Online-Dienste
    • Gebühren
      • Go back
      • Übersicht
      • Europäische Gebühren (EPÜ)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Internationale Gebühren (PCT)
        • Go back
        • Ermäßigung der Gebühren
        • Gebühren für internationale Anmeldungen
        • Beschlüsse und Mitteilungen
        • Übersicht
      • Einheitspatentgebühren (UP)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Gebührenzahlung und Rückerstattung
        • Go back
        • Übersicht
        • Zahlungsarten
        • Erste Schritte
        • FAQs und sonstige Anleitungen
        • Technische Informationen für Sammelzahlungen
        • Beschlüsse und Mitteilungen
        • Versionshinweise
      • Warnung
    • Formblätter
      • Go back
      • Prüfungsantrag
      • Übersicht
    • Zugelassenen Vertreter suchen
  • Recht & Praxis
    • Go back
    • Übersicht
    • Rechtstexte
      • Go back
      • Übersicht
      • Europäisches Patentübereinkommen
        • Go back
        • Übersicht
        • Archiv
          • Go back
          • Übersicht
          • Dokumentation zur EPÜ-Revision 2000
            • Go back
            • Übersicht
            • Diplomatische Konferenz für die Revision des EPÜ
            • "Travaux préparatoires" (Vorarbeiten)
            • Neufassung
            • Übergangsbestimmungen
            • Ausführungsordnung zum EPÜ 2000
            • Gebührenordnung
            • Ratifikationen und Beitritte
          • Travaux Préparatoires EPÜ 1973
      • Amtsblatt
      • Richtlinien
        • Go back
        • Übersicht
        • EPÜ Richtlinien
        • PCT-EPA Richtlinien
        • Richtlinien für das Einheitspatent
        • Überarbeitung der Richtlinien
        • Ergebnisse der Konsultation
        • Zusammenfassung der Nutzerbeiträge
        • Archiv
      • Erstreckungs-/Validierungssystem
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
        • Go back
        • Übersicht
        • Archiv
      • Einheitspatentsystem
        • Go back
        • Travaux préparatoires to UP and UPC
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Go back
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Go back
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Go back
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
  • Neues & Veranstaltungen
    • Go back
    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Go back
      • The meaning of tomorrow
      • Übersicht
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Erfinder kennen
      • Nominierungen
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • Preisverleihung 2024
    • Young Inventors Prize
      • Go back
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die Jury
      • Die Welt, neu gedacht
      • Preisverleihung 2025
    • Pressezentrum
      • Go back
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
        • Go back
        • Übersicht
        • Europäisches Patentamt
        • Fragen und Antworten zu Patenten im Zusammenhang mit dem Coronavirus
        • Fragen und Antworten zu Pflanzenpatenten
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Im Blickpunkt
      • Go back
      • Übersicht
      • Wasserbezogene Technologien
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Übersicht
        • CodeFest 2024 zu generativer KI
        • Codefest 2023 zu grünen Kunststoffen
      • Green tech in focus
        • Go back
        • Übersicht
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
        • Go back
        • Weltraumtechnologie und Patente
        • Übersicht
      • Gesundheit
        • Go back
        • Übersicht
        • Medizintechnik und Krebs
        • Personalised medicine
      • Werkstoffkunde
        • Go back
        • Übersicht
        • Nanotechnologie
      • Mobile Kommunikation
      • Biotechnologie
        • Go back
        • Rot, weiß oder grün
        • Übersicht
        • Die Rolle des EPA
        • Was ist patentierbar?
        • Biotechnologische Erfindungen und ihre Erfinder
      • Patentklassifikation
        • Go back
        • Übersicht
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Übersicht
          • External partners
          • Updates on Y02 and Y04S
      • Digitale Technologien
        • Go back
        • Übersicht
        • Über IKT
        • Hardware und Software
        • Künstliche Intelligenz
        • Vierte Industrielle Revolution
      • Additive Fertigung
        • Go back
        • Übersicht
        • Die additive Fertigung
        • Innovation durch AM
      • Books by EPO experts
    • Podcast
  • Lernen
    • Go back
    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Go back
      • Übersicht
      • Schulungsaktivitäten: Arten und Formate
      • Lernpfade
    • EEP und EPVZ
      • Go back
      • Übersicht
      • EEP – Europäische Eignungsprüfung
        • Go back
        • Übersicht
        • Compendium
          • Go back
          • Übersicht
          • Aufgabe F
          • Aufgabe A
          • Aufgabe B
          • Aufgabe C
          • Aufgabe D
          • Vorprüfung
        • Erfolgreiche Bewerber
        • Archiv
      • EPVZ – Europäisches Patentverwaltungszertifikat
      • CSP – Programm zur Unterstützung von Bewerbern
    • Angebot für bestimmte Interessengebiete
      • Go back
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Patentdurchsetzung und Streitregelung
    • Angebot für bestimmte Zielgruppen
      • Go back
      • Übersicht
      • Geschäftswelt und IP
        • Go back
        • Übersicht
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Fallstudien zum Technologietransfer
          • Fallstudien zu wachstumsstarken Technologien
        • Inventor's handbook
          • Go back
          • Übersicht
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Übersicht
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Übersicht
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EEP und EPVZ Bewerber
        • Go back
        • Übersicht
        • Denkaufgaben zu Aufgabe F
        • Tägliche Fragen zur Aufgabe D
        • Europäische Eignungsprüfung - Leitfaden zur Vorbereitung
        • EPVZ
      • Richter, Anwälte und Staatsanwälte
        • Go back
        • Übersicht
        • Compulsory licensing in Europe
        • Die Zuständigkeit europäischer Gerichte bei Patentstreitigkeiten
      • Nationale Ämter und IP-Behörden
        • Go back
        • Übersicht
        • Lernpfad für Patentprüfer der nationalen Ämter
        • Lernpfad für Formalsachbearbeiter und Paralegals
      • Patentanwaltskanzleien
      • Hochschulen, Forschungseinrichtungen und Technologietransferstellen
        • Go back
        • Übersicht
        • Modularer IP-Ausbildungsrahmen (MIPEF)
        • Programm "Pan-European-Seal für junge Fachkräfte"
          • Go back
          • Übersicht
          • Für Studierende
          • Für Hochschulen
            • Go back
            • Übersicht
            • IP-Schulungsressourcen
            • Hochschulmitgliedschaften
          • Unsere jungen Fachkräfte
          • Beruflicher Entwicklungsplan
        • Akademisches Forschungsprogramm (ARP)
          • Go back
          • Übersicht
          • Abgeschlossene Forschungsprojekte
          • Laufende Forschungsprojekte
        • IP Teaching Kit
          • Go back
          • Übersicht
          • Download modules
        • Handbuch für die Gestaltung von IP-Kursen
        • PATLIB Wissenstransfer nach Afrika
          • Go back
          • Die PATLIB-Initiative "Wissenstransfer nach Afrika" (KT2A)
          • KT2A-Kernaktivitäten
          • Erfolgsgeschichte einer KT2A-Partnerschaft: PATLIB Birmingham und Malawi University of Science and Technology
  • Über uns
    • Go back
    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre EPÜ
      • Go back
      • Official celebrations
      • Übersicht
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Go back
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten
        • Go back
        • Übersicht
        • Mitgliedstaaten sortiert nach Beitrittsdatum
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Go back
      • Übersicht
      • Kommuniqués
        • Go back
        • 2024
        • Übersicht
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Kalender
      • Dokumente und Veröffentlichungen
        • Go back
        • Übersicht
        • Dokumente des Engeren Ausschusses
      • Verwaltungsrat
        • Go back
        • Übersicht
        • Zusammensetzung
        • Vertreter
        • Geschäftsordnung
        • Kollegium der Rechnungsprüfer
        • Sekretariat
        • Nachgeordnete Organe
    • Grundsätze
      • Go back
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategieplan 2028
        • Go back
        • Treiber 1: Personal
        • Treiber 2: Technologien
        • Treiber 3: Qualitativ hochwertige Produkte und Dienstleistungen
        • Treiber 4: Partnerschaften
        • Treiber 5: Finanzielle Nachhaltigkeit
      • Auf dem Weg zu einer neuen Normalität
      • Datenschutzerklärung
    • Führung und Management
      • Go back
      • Übersicht
      • Über den Präsidenten
      • Managementberatungsausschuss
    • Nachhaltigkeit beim EPA
      • Go back
      • Overview
      • Umwelt
        • Go back
        • Overview
        • Inspirierende Erfindungen für die Umwelt
      • Soziales
        • Go back
        • Overview
        • Inspirierende soziale Erfindungen
      • Governance und finanzielle Nachhaltigkeit
    • Beschaffung
      • Go back
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Veröffentlichungen des Dynamischen Beschaffungssystems
      • Nachhaltiger Beschaffungsstandard
      • Über eTendering
      • Rechnungsstellung
      • Beschaffungsportal
        • Go back
        • Übersicht
        • Elektronische Signatur von Verträgen
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Dienste & Aktivitäten
      • Go back
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
        • Go back
        • Übersicht
        • Grundlagen
          • Go back
          • Übersicht
          • Europäisches Patentübereinkommen
          • Richtlinien für die Prüfung
          • Unsere Bediensteten
        • Qualität ermöglichen
          • Go back
          • Übersicht
          • Stand der Technik
          • Klassifikationssystem
          • Tools
          • Qualitätssicherung
        • Produkte & Dienstleistungen
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
          • Fortlaufende Verbesserung
        • Qualität durch Netzwerke
          • Go back
          • Übersicht
          • Nutzerengagement
          • Zusammenarbeit
          • Befragung zur Nutzerzufriedenheit
          • Stakeholder-Qualitätssicherungspanels
        • Charta für Patentqualität
        • Qualitätsaktionsplan
        • Qualitäts-Dashboard
        • Statistik
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
        • Integriertes Management beim EPA
      • Charta unserer Kundenbetreuung
      • Nutzerkonsultation
        • Go back
        • Übersicht
        • Ständiger Beratender Ausschuss beim EPA
          • Go back
          • Übersicht
          • Ziele
          • Der SACEPO und seine Arbeitsgruppen
          • Sitzungen
          • Bereich für Delegierte
        • Befragungen
          • Go back
          • Übersicht
          • Methodik
          • Recherche
          • Sachprüfung, abschließende Aktionen und Veröffentlichung
          • Einspruch
          • Formalprüfung
          • Kundenbetreuung
          • Einreichung
          • Key Account Management (KAM)
          • EPA-Website
          • Archiv
      • Europäische und internationale Zusammenarbeit
        • Go back
        • Übersicht
        • Zusammenarbeit mit den Mitgliedstaaten
          • Go back
          • Übersicht
        • Bilaterale Zusammenarbeit mit Nichtmitgliedstaaten
          • Go back
          • Übersicht
          • Validierungssystem
          • Programm für verstärkte Partnerschaft
        • Internationale Organisationen, Trilaterale und IP5
        • Zusammenarbeit mit internationalen Organisationen außerhalb des IP-Systems
      • Europäische Patentakademie
        • Go back
        • Übersicht
        • Partner
      • Chefökonom
        • Go back
        • Übersicht
        • Wirtschaftliche Studien
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Go back
      • Übersicht
      • Innovation gegen Krebs
      • Akteure im Innovationsbereich
        • Go back
        • Übersicht
        • Start-ups und KMU
      • Politisches Umfeld und Finanzierung
        • Go back
        • Übersicht
        • Programm zur Innovationsfinanzierung
          • Go back
          • Übersicht
          • Unsere Studien zur Innovationsfinanzierung
          • EPA-Initiativen für Patentanmelder/innen
          • Programm zur Innovationsfinanzierung
        • Patente und Normen
          • Go back
          • Übersicht
          • Publikationen
          • Patent standards explorer
      • Tools
        • Go back
        • Übersicht
        • Deep Tech Finder
      • Über die Beobachtungsstelle
        • Go back
        • Übersicht
        • Arbeitsplan
    • Transparency portal
      • Go back
      • Übersicht
      • Allgemein
        • Go back
        • Übersicht
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Übersicht
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Go back
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Geschichte
      • Go back
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Kunstsammlung
      • Go back
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Frühere Ausstellungen
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Lange Nacht"
  • Beschwerdekammern
    • Go back
    • Übersicht
    • Entscheidungen der Beschwerdekammern
      • Go back
      • Neue Entscheidungen
      • Übersicht
      • Ausgewählte Entscheidungen
    • Mitteilungen der Beschwerdekammern
    • Verfahren
    • Mündliche Verhandlungen
    • Über die Beschwerdekammern
      • Go back
      • Übersicht
      • Präsident der Beschwerdekammern
      • Große Beschwerdekammer
        • Go back
        • Übersicht
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technische Beschwerdekammern
      • Juristische Beschwerdekammer
      • Beschwerdekammer in Disziplinarangelegenheiten
      • Präsidium
        • Go back
        • Übersicht
    • Verhaltenskodex
    • Geschäftsverteilungsplan
      • Go back
      • Übersicht
      • Technical boards of appeal by IPC in 2025
      • Archiv
    • Jährliche Liste der Verfahren
    • Mitteilungen
    • Jahresberichte
      • Go back
      • Übersicht
    • Veröffentlichungen
      • Go back
      • Abstracts of decisions
    • Rechtsprechung der Beschwerdekammern
      • Go back
      • Übersicht
      • Archiv
  • Service & Unterstützung
    • Go back
    • Übersicht
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
      • Go back
      • Übersicht
    • FAQ
      • Go back
      • Übersicht
    • Veröffentlichungen
    • Bestellung
      • Go back
      • Patentwissen – Produkte und Dienste
      • Übersicht
      • Allgemeine Geschäftsbedingungen
        • Go back
        • Übersicht
        • Patentinformationsprodukte
        • Massendatensätze
        • Open Patent Services (OPS)
        • Leitfaden zur fairen Nutzung
    • Verfahrensbezogene Mitteilungen
    • Nützliche Links
      • Go back
      • Übersicht
      • Patentämter der Mitgliedstaaten
      • Weitere Patentämter
      • Verzeichnisse von Patentvertretern
      • Patentdatenbanken, Register und Patentblätter
      • Haftungsausschluss
    • Aboverwaltung
      • Go back
      • Übersicht
      • Anmelden
      • Einstellungen verwalten
      • Abmelden
    • Veröffentlichungen
      • Go back
      • Übersicht
      • Möglichkeiten der Einreichung
      • Standorte
    • Offizielle Feiertage
    • Glossar
    • RSS-Feeds
Board of Appeals
Decisions

Recent decisions

Übersicht
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Startseite
  2. Node
  3. T 1291/22 (Oral nutritional composition/ABBOTT) 07-08-2024
Facebook X Linkedin Email

T 1291/22 (Oral nutritional composition/ABBOTT) 07-08-2024

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2024:T129122.20240807
Datum der Entscheidung:
07 August 2024
Aktenzeichen
T 1291/22
Antrag auf Überprüfung von
-
Anmeldenummer
13817809.0
IPC-Klasse
A23L 33/00
Verfahrenssprache
EN
Verteilung
NO DISTRIBUTION (D)

Download und weitere Informationen:

Entscheidung in EN 534.37 KB
Alle Dokumente zum Beschwerdeverfahren finden Sie im Europäisches Patentregister
Bibliografische Daten verfügbar in:
EN
Fassungen
Nicht veröffentlicht
Bezeichnung der Anmeldung

LOW VISCOSITY, HIGH CALORIC DENSITY ORAL NUTRITIONAL COMPOSITION AND RELATED METHODS

Name des Anmelders
ABBOTT LABORATORIES
Name des Einsprechenden

Nutricia Research B.V.

Fresenius Kabi Deutschland GmbH

Kammer
3.3.09
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 123(2)
European Patent Convention Art 83
European Patent Convention Art 54
European Patent Convention Art 56
Rules of procedure of the Boards of Appeal Art 12(4)
Rules of procedure of the Boards of Appeal Art 12(6)
Rules of procedure of the Boards of Appeal Art 13(2)
Schlagwörter

Amendments - allowable (yes)

Sufficiency of disclosure - (yes)

Novelty - (yes)

Inventive step - non-obvious modification

Orientierungssatz
-
Angeführte Entscheidungen
T 2399/10
T 0797/14
T 0842/14
Anführungen in anderen Entscheidungen
-

Summary of Facts and Submissions

I. This decision concerns the appeals filed by opponents 1 and 2 (appellants 1 and 2) against the opposition division's interlocutory decision that the European patent as amended met the requirements of the EPC.

II. With their respective notice of opposition, opponents 1 and 2 had requested that the patent be revoked under Article 100(a) (lack of novelty and lack of inventive step), (b) and (c) EPC.

III. The documents submitted during the opposition proceedings included:

D1:|WO 2009/072885 A1 |

D5:|Mintel database: Record ID 1012294 ("Abbott Ensure TwoCal")|

D6:|WO 2010/140891 A2|

D16:|WO 2009/072886 A1|

D26:|WO 2012/008858 A1|

IV. In the decision under appeal, auxiliary request 1 (filed by letter dated 25 September 2020) was found to be allowable. This request is the main request on appeal.

V. The wording of product claims 1, 3 and 8 of the main request is relevant to this decision, and is set out below.

"1. A low viscosity, high caloric density liquid nutritional composition comprising:

a) protein in an amount of between 8 to 27 grams per 100 mL of the nutritional composition, the protein comprising (i) non-micellar milk protein isolate, non-micellar milk protein concentrate, or both, and (ii) a partially hydrolyzed caseinate; wherein the protein comprises 0-25% by weight of protein from a partially hydrolyzed caseinate; 25-50% by weight of protein selected from the group consisting of whey protein, soy protein, pea protein, potato protein and combinations thereof; and 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof;

b) fat in an amount of between 0 and 17 grams per 100 mL of the nutritional composition; and

c) at least one emulsifier selected from the group consisting of lecithin, monoglycerides, diglycerides, polyglycerol esters, milk phospholipids, citric acid esters, datem and emulsifiers with a hydrophilic-lipophilic balance between 5 and 16, and combinations thereof;

wherein the nutritional composition has a viscosity of between 45 and 140 cps at 22 C, a caloric density of 200 to 300 kcal per 100 mL of the nutritional composition, and wherein the total combined amount of fat and protein is 8-27 grams per 100 mL of the nutritional composition."

"3. A low viscosity, high caloric density liquid nutritional composition according to claim 1, wherein the non-micellar protein is denatured through one or more of hydrolysis, heat treatment, homogenization, or reaction with soluble divalent minerals."

"8. A low viscosity, high caloric density liquid nutritional composition comprising:

a) protein in amount of between 8 to 27 grams per 100 mL of the nutritional composition;

b) fat in an amount of between 0 and 17 grams per 100 mL of the nutritional supplement;

c) an anti-foaming agent selected from the group consisting of simethicone, dimethylpolysiloxane, silicone dioxide, lecithin, milk phospholipid, and combinations thereof; and

d) a chelating agent selected from the group consisting of monovalent chelating agents, divalent chelating agents, and combinations thereof; in an amount of 0.3 weight% to 0.5 weight%;

where the protein comprises: 50-75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof; and

partially hydrolyzed caseinate in an amount of up to 50% by weight of partially hydrolyzed caseinate, or up to 25% by weight of partially hydrolyzed caseinate and 0-25% by weight of at least one protein selected from the group consisting of: micellar milk protein, non-hydrolyzed caseinate, soy, pea, whey, rice, corn, meat, fish, egg albumen, potato, canola, algal protein, mycoprotein and combinations thereof;

wherein the nutritional composition has a viscosity of between 45 and 140 cps at 22 C; wherein the composition has a caloric density of 200 to 300 kcal per 100 mL of the nutritional supplement; and wherein the total combined amount of fat and protein is 8-27 grams per 100 mL of the nutritional composition."

Claim 15 is an independent claim directed to a method for manufacturing a low viscosity, high caloric density liquid nutritional composition. The method involves the the step of adding protein comprising partially hydrolysed caseinate and non-micellar milk protein selected from the group consisting of non-micellar milk protein isolate, non-micellar milk protein concentrate, and combinations thereof. The wording of this claim is not relevant.

VI. On appeal, the patent proprietor (respondent) filed nine auxiliary requests (numbered 1 to 9). Among other things, appellant 2 filed the following document after notification of the board's communication under Article 15(1) RPBA:

D29:|K. Smith, "Dried Dairy Ingredients", Wisconsin Center for Dairy Research, 2008, 5 and 20|

VII. The following arguments were raised against the claims of the main request.

- Appellant 2 argued that claim 3 did not comply with the requirement of Article 123(2) EPC. This claim was a combination of claims 1, 3 and 4 of the application as filed. There was no basis in the application as filed for this combination.

- Appellant 1 argued that claim 8 did not comply with the requirement of Article 123(2) EPC and that claim 1 did not comply with the requirement of Article 123(3).

- Appellants 1 and 2 asserted that even when taking the description of the patent into consideration, the skilled person would not have known how to provide the non-micellar protein called for in the claims. In particular, the milk protein isolate and milk protein concentrate used in the examples of the patent were apparently in micellar form. Non-micellar milk protein isolate and non-micellar milk protein concentrate were not commercially available.

- Appellants 1 and 2 maintained that partially hydrolysed caseinate was not a mandatory feature of claims 1 and 8. The compositions claimed did not need to comprise this ingredient. It followed from this that the subject-matter of claims 1 and 8 lacked novelty over D26. In addition, appellant 1 considered these claims to lack novelty over D1.

- Appellants 1 and 2 stated that inventive step could be assessed from any of documents D1, D6, D16 or D26. Appellant 1 used D1 and D26 as starting points to outline its objections of a lack of inventive step. Appellant 2 based its objections of a lack of inventive step on either D6 or D26 as a starting point. In all cases, the conclusion was that claim 1 lacked an inventive step and the same applied to claims 8 and 15.

VIII. The respondent's arguments, where relevant to the decision, can be summarised as follows:

- Claim 3 did comply with the requirement of Article 123(2) EPC. No new combination of features was generated by the amendment in claim 1.

- Appellant 1's objections against claim 8 under Article 123(2) EPC and against claim 1 under Article 123(3) EPC had not been made prior to the appeal proceedings. They should not be admitted on appeal.

- The skilled person would have known how to produce and identify the non-micellar milk protein products called for in the claim. They simply had to break down the micellar structure of the specified protein.

- The subject-matter of claims 1 and 8 was novel. It was clear from both the wording of the claims and the patent's description that partially hydrolysed caseinate was a mandatory feature of these claims.

- The subject-matter of claims 1, 8 and 15 did involve an inventive step. The closest prior art was example 2 of D26. There were numerous distinguishing features, including the inclusion of partially hydrolysed caseinate. D1 and D6 required micellar caseinate and were not the closest prior art.

IX. Final requests

Appellants 1 and 2 requested that the decision under appeal be set aside and that the patent be revoked.

The respondent requested that the appeal be dismissed (main request) or, alternatively, that the patent be maintained in amended form based on the claims of one of auxiliary requests 1 to 4 as filed with the reply to the appellants' statements setting out the grounds of appeal, or of one of auxiliary requests 5 to 9 as filed by letter dated 7 March 2024.

Reasons for the Decision

1. Patent in suit

1.1 The patent is directed to nutritional compositions displaying high caloric density and low viscosity, and a method for manufacturing such compositions.

1.2 Product claims 1 and 8 of the main request are directed to compositions in which the protein comprises 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination thereof, and specified amounts of further protein components. Method claim 15 of the main request is directed to a method for manufacturing a low viscosity, high caloric density liquid nutritional composition. The method involves the step of adding protein comprising partially hydrolysed caseinate and non-micellar milk protein.

2. Claim interpretation

2.1 In the decision under appeal, the opposition division acknowledged that there was a discrepancy in claim 1 of the current main request; while claim 1 included the value 0% of a partially hydrolysed caseinate, this ingredient was listed as being compulsory in the nutritional composition of claim 1. However, taking the patent specification into consideration, the range "0-25%" had to be interpreted as "more than 0 to 25%".

2.2 This part of the decision was contested and the following arguments were presented.

2.2.1 The wording used in claim 1 ("comprises 0-25% by weight of protein from a partially hydrolyzed caseinate") meant that the composition of claim 1 did not necessarily comprise partially hydrolysed caseinate. The value 0% made it clear that partially hydrolysed caseinate was merely an optional ingredient of the composition of claim 1.

2.2.2 Moreover, if there were two possible interpretations, then for legal certainty the broader interpretation had to be applied, to the patent proprietor's disadvantage.

2.2.3 Furthermore, the patent's description endorsed the interpretation that partially hydrolysed caseinate was an optional ingredient. Firstly, example 2 of the patent did not (explicitly) disclose that the caseinate used was partially hydrolysed. Secondly, the patent specification referred to two passages of paragraph [0024] of the patent that confirmed this understanding and read as follows:

"When used in the disclosed liquid nutritional compositions, the partially hydrolyzed caseinate ..."

"When present in the disclosed embodiments, the partially hydrolyzed caseinate..." (emphasis added).

2.2.4 Finally, claim 8 did not require partially hydrolysed caseinate as a mandatory feature.

2.3 Interpretation of claim 1

2.3.1 Claim 1 of the application as filed and claim 1 as granted relate to a low viscosity, high caloric density liquid nutritional composition which comprises, among other things,

(i) non-micellar milk protein isolate, non-micellar

milk protein concentrate, or both, and

(ii) a partially hydrolysed caseinate

2.3.2 During the first-instance opposition proceedings, claim 1 as granted was restricted by the addition of features from dependent claim 3 as granted. Among other features, the amount of partially hydrolysed caseinate ("0-25% by weight of protein from a partially hydrolyzed caseinate") was added to claim 1.

2.3.3 Due to this amendment, claim 1 of the main request encompasses the feature:

"(i) non-micellar milk protein isolate, non-micellar milk protein concentrate, or both, and (ii) a partially hydrolyzed caseinate; wherein the protein comprises 0-25% by weight of protein from a partially hydrolyzed caseinate ..." (emphasis added by the board).

2.3.4 A straightforward reading of claim 1 imposes a specific hierarchy of the features in this claim. It is plain to see that the two ingredients (i) and (ii) of the composition of claim 1 are necessarily part of the composition.

2.3.5 After the semicolon, further features of claim 1 are specified. Among other things, the weight% distribution of the various proteins that form the composition's protein fraction is specified. In other words, the semicolon imposes a sequential reading of the claim, which involves two separate requirements. The first requirement is that partially hydrolysed caseinate is part of the composition of claim 1. This first requirement is restricted - but not eliminated - by the second requirement, namely that the amount is necessarily 0 to 25% by weight of the protein.

2.3.6 Given the specific wording and structure, claim 1 is considered to specify that the partially hydrolysed caseinate cannot be left out of the composition according to claim 1. On the contrary, it is a mandatory ingredient of claim 1. Therefore, in this claim the value 0% has to be read and understood as meaning "above 0%" (or starting from 0%, with 0% being excluded). This is the interpretation which the opposition division correctly adopted.

2.3.7 As an intermediate conclusion, it is plain to see from the wording of claim 1 alone that partially hydrolysed caseinate is a mandatory ingredient. Contrary to the appellants' view, there is only one interpretation that applies.

2.3.8 For completeness, it is noted that the patent specification supports this interpretation.

2.3.9 All three embodiments discussed in detail in the patent (paragraphs [0006] to [0008] and [0010] to [0012]) unambiguously disclose that partially hydrolysed caseinate is a mandatory ingredient. The passage to which appellant 2 referred, paragraph [0024], corroborates this. It starts as follows:

"As previously discussed, according to the first, second and third embodiments, the compositions include a partially hydrolysed caseinate".

2.3.10 Within the context of this paragraph, the features specified after the terms "[w]hen used" and "[w]hen present" (see section 2.2.3 above) are understood to define the specific partially hydrolysed caseinate that is added to the compositions of the patent. These features are not to be understood as definitions of partially hydrolysed caseinate that apply in general, i.e. outside the context of the patent and its compositions.

2.3.11 Finally, while example 2 of the patent does not explicitly disclose that the sodium caseinate used therein is partially hydrolysed, this alone cannot serve to confirm that partially hydrolysed caseinate is merely an optional ingredient of claim 1.

2.3.12 To conclude, in the context of claim 1, the value 0% has to be read and understood as meaning "above 0%".

2.4 Interpretation of claim 8

2.4.1 The appellants gave no specific reasoning for their assessment that according to claim 8 partially hydrolysed caseinate was an optional feature.

2.4.2 Claim 8 discloses that the amount of partially hydrolysed caseinate is "up to 50%" or "up to 25%", depending on the embodiment. Similar considerations to those set out with respect to claim 1 apply to the wording of claim 8. The maximum amount of partially hydrolysed caseinate ("up to 50%" or "up to 25%") in the context of claim 8 implies that the amount of this ingredient is not 0%; partially hydrolysed caseinate is a mandatory ingredient.

2.5 To conclude on claim interpretation, independent claims 1 and 8 of the main request call for partially hydrolysed caseinate as a mandatory ingredient of the low viscosity, high caloric density liquid nutritional composition. This claim interpretation will be used in the following.

3. Admittance of D29

3.1 Appellant 2 filed document D29 after notification of the board's communication under Article 15(1) RPBA. The respondent argued that this document should not be admitted into the proceedings.

3.2 Appellant 2 did not refer to any exceptional circumstances justifying the filing of this document. It had filed D29 merely to demonstrate that according to common general knowledge, to which D29 allegedly belonged, milk protein concentrate and milk protein isolate contained micellar casein and whey protein.

3.3 However, Article 13(2) RPBA makes no exception for documents considered by a party to be proof of common general knowledge. In addition, the typical composition of conventional milk protein concentrate and milk protein isolate as such is not in dispute.

3.4 Therefore, the board cannot see any reason to take this document into account in these proceedings (Article 13(2) RPBA).

4. Main request - amendments

4.1 The opposition division decided that the claims of what was then auxiliary request 1 (now the main request) complied with the requirement of Article 123(2) EPC.

4.2 Appellant 2 argued that claim 3 involved added subject-matter. Appellant 1 argued that claim 8 involved added subject-matter.

4.3 Amendment to claim 3

4.3.1 According to appellant 2, claim 3 (of the main request) was based on claim 4 of the application as filed. Claim 1 of the main request was based on a combination of claims 1 and 3 of the application as filed. It followed from this that claim 3 of the main request was a combination of claims 1, 3 and 4 of the application as filed, for which there was no basis in the application as filed.

4.3.2 It is true that claim 4 of the application as filed is not dependent on claim 3 of the application as filed. However, claim 4 of the application as filed discloses possible measures for preparing non-micellar milk protein. The only non-micellar milk proteins mentioned both in the application as filed and in the patent are non-micellar milk protein isolate and non-micellar milk protein concentrate. Therefore, claim 3 of the main request simply sets out the different ways the non-micellar protein of claim 1 of the main request can be made.

4.3.3 Paragraph [0017] of the application as filed further supports this general teaching. While further features are disclosed in this paragraph on how non-micellar proteins are prepared (e.g. homogenisation conditions), the skilled person would realise that they would not be obliged to apply all the specific embodiments or conditions taught in this paragraph. The teaching in claim 4 of the application as filed is generic.

4.3.4 Therefore, claim 3 of the main request does not encompass added subject-matter. Its combination with the subject-matter of claim 1 of the main request would be directly and unambiguously derivable for the skilled person.

4.4 Amendment to claim 8

4.4.1 Appellant 1 did not raise any objection of added subject-matter with respect to claim 8 of auxiliary request 1 before the opposition division; it did so only on appeal. The respondent argued that this was a new objection which should not be admitted into the proceedings.

4.4.2 As is clear from the minutes of the oral proceedings before the opposition division and the decision under appeal, no objection of added subject-matter was raised against claim 8, despite the fact that the claim wording had been known to the opponents for more than a year before the oral proceedings. Thus, appellant 1 could and should have presented its objection during the opposition proceedings.

4.4.3 Therefore, this objection was not admitted on appeal (Article 12(4) and (6) RPBA).

4.5 To conclude, the main request complies with the requirement of Article 123(2) EPC.

5. Main request - requirement of Article 123(3) EPC

5.1 In the decision under appeal (point 19.2.1), it is stated that the opponents had no objections under Article 123(3) EPC. However, in its statement setting out the grounds of appeal, appellant 1 did raise such an objection. The respondent argued that this new objection should not be admitted into the proceedings.

5.2 Appellant 1's objection raised on appeal represents an amendment to its appeal case. It could and should have presented its objection during the opposition proceedings.

5.3 Therefore, this objection was not admitted into the proceedings (Article 12(4) and (6) RPBA).

6. Main request - sufficiency of disclosure

6.1 The opposition division concluded that the invention set out in the claims corresponding to the current main request met the requirement of Article 83 EPC.

6.2 The appellants contested this conclusion and presented the following arguments.

6.2.1 Even when taking the description of the patent into consideration, the skilled person would not have known how to provide the non-micellar protein called for in the claims. In particular, the milk protein isolate and milk protein concentrate used in the examples of the patent were apparently in micellar form. The non-micellar protein of claim 1 was not commercially available. Decisions T 2399/10, T 797/14 and T 842/14 were cited to support these arguments.

6.2.2 In the course of the appeal proceedings and during the oral proceedings before the board, appellant 2 further refined its line of argument. It conceded that preparing non-micellar protein was trivial. However, according to common general knowledge the casein in milk protein isolate and milk protein concentrate was in micellar form. It followed from this that the skilled person would not have known how to resolve the contradiction and produce non-micellar milk protein isolate or non-micellar milk protein concentrate.

6.3 The arguments provided by the appellants have not convinced the board.

6.4 First and foremost, the skilled person knows how to destroy the micellar structure of proteins. Appellant 2 itself confirmed this during the oral proceedings before the board.

6.5 Therefore, to provide the non-micellar components of claim 1, all the skilled person has to do is break down (or denature) the micellar structure which is intrinsic to the milk protein isolate and milk protein concentrate. This way, the micellar structure originally contained in these proteins is destroyed. The resulting proteins are a non-micellar milk protein isolate and a non-micellar milk protein concentrate.

6.6 In doing this, the skilled person is not bound to instructions in the patent in suit. Instead, they can use their common general knowledge and known methods such as calcium depletion.

6.7 Against this background, it is conclusive that the patent outlines only in very generic terms what can be done to provide the non-micellar components of claim 1 ("hydrolysis, heat treatment, reaction with soluble divalent minerals, and combinations thereof" (paragraph [0018]).

6.8 As the respondent explained, micelles are identified by microscopy - and if they are not detected, then the protein examined is non-micellar. While this is not explicitly disclosed in the patent in suit, it is something that the skilled person would straightforwardly understand upon reading the patent. In view of this, the board does not consider there to be an undue burden for the skilled person to provide nutritional compositions in which the protein comprises 50 to 75% by weight of non-micellar milk protein isolate, non-micellar milk protein concentrate or a combination of the two.

6.9 On this basis, the board cannot identify any lack of sufficiency of disclosure.

6.10 For completeness, the following observations are made with respect to the additional arguments provided by the appellants.

6.10.1 Given that the skilled person can prepare the non-micellar milk protein isolate and non-micellar milk protein concentrate required by claim 1, it is not relevant whether such products can be bought. Nor is it relevant to assess whether the specific commercial milk protein products used in the examples are in a non-micellar form.

6.10.2 It follows from this that decision T 842/14, as cited by the appellants, is not relevant. This decision concerns a case in which the chemical composition of the anti-foam reagents of claim 1 was "made available to the skilled person, if at all, only by being commercially available" (Reasons, 32). In the current case, the situation is different. A specific, commercial product is not required by claim 1, and the skilled person would not be obliged to carry out the invention with a product that they cannot prepare themselves and would have to purchase.

6.10.3 For analogous reasons, T 797/14 is not relevant either. In the case underlying this decision, the preferred and unique coating composition was a product commercialised under a specific trade mark. Its composition and method of production was not public knowledge and was kept secret by the manufacturer. However, this is not the case with the non-micellar protein required by claim 1.

6.10.4 The appellants also referred to T 2399/10. However, this decision is not applicable in the current case either. T 2399/10 refers to an insufficiently disclosed dimensional parameter. The competent board considered that the method for establishing the parameter was neither disclosed in the patent nor to be found in the prior art. In contrast, the terms "non-micellar milk protein concentrate" and "non-micellar milk protein isolate" in the present case are not parameters. Rather, the terms denote a protein that is treated such that it is no longer in the form of micelles. As discussed above, such a protein can be prepared by the skilled person.

6.11 Finally, it is noted that in the decision under appeal it is stated that "calcium-depleted MPC of D26 was considered by all parties as a non-micellar MPC" (Reasons, 19.6.3). D26 is a prior-art document which was used as the closest prior art in the decision under appeal.

6.11.1 For the board, this confirms that in the field of liquid nutritional compositions, the skilled person would have known what a non-micellar milk protein concentrate ("non-micellar MPC") is. They would have been able to identify it in the prior art.

6.11.2 At this juncture it is also noted that the process for obtaining the calcium-depleted milk protein concentrate of D26 disclosed in claim 1 involves both a heat treatment and removal of calcium ions. This corresponds to the process steps for producing non-micellar protein outlined in the patent (see point 6.7 above).

6.12 To conclude, the invention is disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art (Article 83 EPC).

7. Main request - novelty

7.1 The opposition division concluded that claim 1 was novel over D1 and D26, among other documents. The appellants contested this.

7.2 The arguments of appellants 1 and 2 on a lack of novelty are based on the interpretation that partially hydrolysed caseinate is not a mandatory ingredient of the composition of claim 1. As explained in point 2 above, the board does not agree with this interpretation.

7.3 Neither D1 nor D26 discloses at least the feature of partially hydrolysed caseinate. Furthermore, the appellants' argument that the caseinate disclosed in D1 and D26 implicitly includes fragments of caseinate which the skilled person would then consider to be (trace amounts of) partially hydrolysed caseinate was not convincing. This is not what the skilled person would directly and unambiguously derive from the disclosure of D1 and D26.

7.4 On this basis, and in agreement with the opposition division's conclusion, the subject-matter of claim 1 is found to be novel over the disclosure of D1 and D26 (Article 54 EPC).

8. Main request - inventive step

8.1 The opposition division concluded that the subject-matter of claims 1 and 8 of the current main request involved an inventive step. D26 was considered to be the closest prior art. Nevertheless, the opposition division also discussed approaches starting from other documents.

8.2 The appellants stated that inventive step could be assessed starting from any of documents D1, D6, D16 or D26.

8.3 Selection of the closest prior art

8.3.1 The assessment of inventive step starting from more than one document should be the exception rather than the rule. In the current case, the opposition division identified D26 as the closest prior art. Among the documents referred to by the appellants for assessing inventive step, this is the only document that relates to a liquid nutritional composition which comprises calcium-depleted (i.e. non-micellar) milk protein concentrate (see also section 6.11 above).

8.3.2 Therefore, D26 is used as the closest prior art in the following.

8.3.3 Neither D1 nor D6 is suitable as a starting point for assessing inventive step. Both documents disclose micellar casein as a mandatory ingredient. This runs counter to the subject-matter claimed and, thus, to the purpose of the patent. In fact, in order to arrive at the claimed subject-matter starting from D1 or D6, the skilled person would have to replace large amounts (or even all) of the mandatory ingredients of micellar casein. In other words, the skilled person would have to depart from the core teaching of these two documents.

8.3.4 Appellant 2 did not set out why it considered D16 to be the closest prior art and why the claimed subject-matter was obvious starting from this document. In the absence of reasoning as to why the opposition division's conclusions were incorrect, this objection does not have to be considered.

8.3.5 To sum up, the board agrees with the opposition division that D26 is to be considered the closest prior art.

8.4 Closest prior art and distinguishing features

8.4.1 As discussed during the oral proceedings before the board, example 2 of D26 is the fat-containing, high caloric density composition from which the assessment of inventive step is to begin. The liquid nutritional composition disclosed in this example comprises calcium-depleted (i.e. non-micellar) milk protein concentrate as the only source (i.e. 100%) of protein. In view of this, the calcium-depleted protein does not provide 50 to 75% by weight of protein of non-micellar milk protein isolate or non-micellar milk protein concentrate.

8.4.2 Accordingly, claim 1 differs from example 2 of D26 at least by the following features:

- partially hydrolysed caseinate, in an amount of up to 25% by weight of protein

- non-micellar milk protein isolate or non-micellar milk protein concentrate or both, in an amount of 50 to 75% by weight of protein

- whey protein, soy protein, pea protein, potato protein or combinations thereof, in an amount of 25 to 50% by weight of protein

8.5 Technical effect and problem to be solved

8.5.1 It was in dispute between the parties whether the distinguishing features provided any specific technical effect. The patent proprietor's position was that this was the case, whereas the appellants took the view that the distinguishing features simply resulted in a further alternative to the composition of D26.

8.5.2 The opposition division regarded the objective technical problem as being to provide an alternative nutritional composition having high nutritional caloric density and a reduced viscosity. For the sake of argument, and in favour of the appellants' line of argument, the board will start from the same assumption. Considering that the subject-matter of claim 1 is found to involve an inventive step on this basis alone, it is not necessary to decide whether the distinguishing features bring about any additional technical effect.

8.5.3 At the oral proceedings before the board, appellant 2 argued that in view of the distinguishing features, partial problems had to be formulated. The aim of formulating two problems was to call out two different, sequential selections of ingredients replacing the calcium-depleted milk protein concentrate of D26. However, as the problem formulated by the board does not in itself exclude a sequential selection of ingredients, the question of whether partial problems should be formulated can remain open.

8.5.4 To conclude, the problem to be solved is to provide an alternative nutritional composition having high nutritional caloric density and a reduced viscosity.

8.6 Non-obviousness

8.6.1 In D26, the use of 100% calcium-depleted milk protein is preferred (as in example 2). However, page 8 (lines 13 to 16) of D26 discloses that "[o]ther protein that may be included in amounts up to 49% include whey proteins, preferably provided from a whey protein concentrate ...". Therefore, the only protein explicitly mentioned in D26, aside from the calcium-depleted milk protein concentrate, is whey protein. This protein may be provided as a whey protein concentrate.

8.6.2 Considering that D26 prefers the use of a single protein, namely calcium-depleted milk protein concentrate, the board cannot identify any motivation to add whey protein and then also a third protein, i.e. partially hydrolysed caseinate, while expecting the composition to still have a suitable viscosity. On this basis, the skilled person would not have been motivated to add up to 25% by weight of protein of a partially hydrolysed caseinate to the composition of D26.

8.6.3 The combination of the closest prior art with D6, for example, does not render obvious the subject-matter of claim 1 either. D6 requires high amounts of micellar casein as a mandatory ingredient and only mentions intact caseinate, whereas D26 suggests preferably using only calcium-depleted milk protein concentrate. The skilled person would not have made the adjustments the appellants suggested because this would have meant combining somewhat opposed teachings.

8.6.4 The main line of argument of appellant 2 on obviousness was that it would be obvious to replace part of the calcium-depleted milk protein concentrate by (intact) sodium caseinate. In this context, several documents were cited, including D1, D5 and D16. All these documents showed that (sodium) caseinate was commonly used in liquid enteral compositions having high energy and a high protein content. Appellant 2 further maintained that commercially available caseinates intrinsically comprised a certain amount of partially hydrolysed caseinate. It followed from this that adding caseinate led to the subject-matter of claim 1.

8.6.5 However, as already explained above, it is not convincing that starting from example 2 of D26, the skilled person would not only add whey protein but also a further, third protein. Nor is it convincing that they would replace part of the calcium-depleted milk protein concentrate with two proteins, whey protein and a further protein, namely (intact) sodium caseinate. On this basis alone, the subject-matter of claim 1 is considered to involve an inventive step.

8.6.6 In view of this, it is not necessary to decide whether adding (intact) caseinate would provide a liquid nutritional composition protein that necessarily falls under claim 1, having regard to the broad definition of partially hydrolysed caseinate of paragraph [0024] of the patent ("the term 'partially hydrolyzed caseinate' refers to a caseinate in which a portion of the protein has been hydrolyzed ... e.g., 0.5 to 10% hydrolyzed").

8.6.7 In sum, starting from the closest prior art, the subject-matter of claim 1 cannot be regarded as obvious (Article 56 EPC).

8.7 With regard to claims 8 and 15, no different, specific lines of argument were provided. It follows from this that the same conclusions as those set out with respect to claim 1 also apply to claims 8 and 15.

8.8 To conclude, the subject-matter of claims 1, 8 and 15 involves an inventive step (Article 56 EPC).

Entscheidungsformel

Order

For these reasons it is decided that:

The appeals are dismissed.

Footer - Service & support
  • Unterstützung
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
    • FAQ
    • Veröffentlichungen
    • Verfahrensbezogene Mitteilungen
    • Kontakt
    • Aboverwaltung
    • Offizielle Feiertage
    • Glossar
Footer - More links
  • Jobs & Karriere
  • Pressezentrum
  • Single Access Portal
  • Beschaffung
  • Beschwerdekammern
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Impressum
  • Nutzungsbedingungen
  • Datenschutz
  • Barrierefreiheit